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ABSTRACT
Erythropoietin (EPO) is neuroprotective in models of stroke and traumatic brain injury (TBI) when
administered prior to or within the first few hours after injury. We seek to demonstrate that EPO
also has neurorestorative effects when administered late (i.e., 1 day) after TBI in the rat. Twelve
rats were subjected to TBI. Six rats were treated with EPO daily for 14 days starting 1 day after
injury, and an additional six rats were treated with saline. Bromodeoxyuridine (BrdU) was admin-
istered daily for 14 days. Memory tests using a Morris Water Maze were performed prior to and
after injury and treatment. Animals were sacrificed at 15 days after TBI, and their brains were pre-
pared for histological analysis of damage to the dentate gyrus (DG) and for evaluation of newly
formed neurons using double labeling of BrdU and MAP-2. The data revealed a significant im-
provement in spatial memory and significant increase in the number of newly formed neurons with
EPO treatment compared with control animals. These data suggest that EPO treatment initiated 1
day after TBI is neurorestorative by enhancing neurogenesis, as well as neuroprotective.
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INTRODUCTION
A
LTHOUGH A NUMBERof therapeutic trials for TBI have
been undertaken, no broadly applicable, safe, and ef-
ficacious treatment has been identified (Narayan et al.,
2002). Recently, attention has focused on potential ther-
apeutic agents that enhance endogenous neuroplasticity
including neurogenesis, angiogenesis, and synaptogene-
sis after brain injury (Yoshimura et al., 2003; Hallberg-
son et al., 2003; Lu et al., 1999). Erythropoietin (EPO)
and its receptors are present in the human cerebral cor-
tex and are up-regulated following hypoxic stimuli
(Jumbe 2002; Sasaki et al., 2000, 2001; Brines et al.,
2000; Tong and Nissenson, 2001; Mulcahy, 2000). In an-
imal models, administration of recombinant human EPO
prior to or within the first 3 h after onset of experimen-
tal global and focal cerebral ischemia as well as traumatic
brain injury (TBI) is neuroprotective (Brines et al., 2000;
Dame et al., 2001; Cerami et al., 2002; Wang et al., 2004).
These findings suggest that exogenous administration of
erythropoietic agents may be a potential therapeutic tool
for central nervous system injury (Jumbe, 2002). Sys-
temic administration of epoetin alla, a derivative of eryth-
ropoietin, reduced concussive brain injury (Cerami et al.,2002). However, previous studies focused on the neuro-
protective effect of EPO administered before and imme-
diately after brain injury. We have demonstrated that EPO
is effective in improving neurological recovery in the rat
after middle cerebral arterial occlusion and also enhances
neuroplasticity (Wang et al., 2004a,b). In addition, a
novel nonhematopoietic EPO, CEPO, has been shown to
significantly improve neurological recovery in animal
models of stroke, spinal cord injury and multiple sclero-
sis (Leist et al., 2004). Whether EPO reduces cognitive
deficits and enhances neuroplasticity in the rat after TBI
has not been investigated.
In this study, Wistar rats subjected to controlled corti-
cal impact were treated with EPO starting one day after
TBI. Our data show that EPO significantly improves spa-
tial memory and concomitantly increases neurogenesis in
the dentate gyrus (DG) in rats subjected to controlled cor-
tical impact TBI.
MATERIALS AND METHODS
Animal Models
A controlled cortical impact model of TBI in rat was
utilized in the present study (Dixon et al., 1991; Mah-
mood et al., 2001). Male Wistar rats (300–400 g) were
anesthetized with 350 mg/kg/body weight chloral hy-
drate, intraperitoneally. Rectal temperature was con-
trolled at 37°C with a feedback-regulated water-heat-
ing pad. A controlled cortical impact device was used
to induce the injury. Briefly, rats were placed in a
stereotactic frame. Two 10-mm-diameter craniotomies
were performed adjacent to the central suture, midway
between lambda and bregma. The second craniotomy
allowed for movement of cortical tissue laterally. The
dura was kept intact over the cortex. Injury was induced
by impacting the left cortex (ipsilateral cortex) with a
pneumatic piston containing a 6-mm-diameter tip at a
rate of 4 m/sec and 2.5 mm of compression. Velocity
was measured with a linear velocity displacement trans-
ducer.
Experimental Groups
Based on earlier studies (Cerami et al., 2002; Wang et
al., 2004a), we selected a daily dose of 5000 IU/kg EPO
as a treatment protocol. Twelve rats were randomly di-
vided into two groups (6 rats/group): TBI   saline and
TBI   EPO. In the TBI   EPO group, rats received 5000
IU/kg EPO intraperitoneally, starting 1 day after TBI and
then daily for 14 days. These rats also received 100 mg/kg
bromodeoxyuridine (BrdU) intraperitoneally, starting 1
day after TBI, then daily for 14 days. Rats in the TBI  
saline group received the same BrdU and saline injection
without EPO.
Tissue Preparation
Rats were anesthetized intraperitoneally with ketamine
and xylazine, and perfused transcardially first with saline
solution containing heparin, followed by 4% paraform-
aldehyde in 0.1 M phosphate buffered saline (PBS), pH
7.4. Their brains were removed, post-fixed in 10% for-
malin for 1–2 days at room temperature, and then
processed for paraffin sectioning.
Floating Section Staining
A series of 50- m-thick sections were cut with a mi-
crotome through the dorsal hippocampus containing the
DG. Three sections with a 100- m interval were selected
and processed for the floating section staining. Briefly, the
sections were deparaffinized in xylene and alcohol, and
rinsed in PBS followed by incubation in 0.1% sapornin for
3 days. The sections were then treated with 50% for-
mamide in 2   SSC at 65°C for 60 min, 2 N HCL at 37°C
for 20 min and 0.1 M boric acid at room temperature for
3 min. After washing with PBS, 0.3% Triton-1% BSA in
PBS was added to block the nonspecific signals at room
temperature for 3 h. Mouse anti-BrdU antibody (1:200,
DAKO) and rabbit anti-NeuN antibody (1:100, Chemicon)
were added and incubated at 4°C for 3 days. After wash-
ing, FITC-conjugated anti-mouse antibody (green for
BrdU) and CY5-conjugated anti-rabbit (red for NeuN) an-
tibodies were added on the sections (1:200, Jackson Im-
muno) at 4°C for an additional 3 days. After washing, the
sections were washed and mounted with Glycergel. Im-
ages were collected with laser confocal microscopy.
Image Acquisition and Analysis
The stained sections were analyzed with a Bio-Rad
MRC 1024 (argon and krypton) laser-scanning confocal
imaging system mounted onto a Zeiss microscope (Bio-
Rad, Cambridge, MA). Sections from each animal were
scanned throughout the entire hippocampus in 512  
512-pixel (1,042.4   1,042.4   m) format using a 4 
frame-scan average, and 20 optical sections with a 5- m
step-size under a 40  objective and FITC and Cy5-la-
beled cells were acquired with photomultiplier tubes.
FITC and Cy5 fluorochromes on the sections were ex-
cited by laser beams at 488 and 530 nm. A series of im-
ages was obtained along the DG and subsequently
merged using cofocal assistant software. A total of BrdU-
only labeled cells (green) and the BrdU and NeuN cola-
beled cells (yellow) were counted, respectively, in the ip-
silateral DG. The average numbers of the three slides
were used for statistical analysis.
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The testing procedure is a modification of the Morris
Water Maze tests, described previously (Day et al., 1999;
Day and Schallert, 1996; Yamada et al., 1999; Lu et al.,
2004). The experimental apparatus consists of a circular
water tank (140 cm in diameter and 45 cm high). An in-
visible platform (15 cm in diameter and 35 cm high) was
placed 1.5 cm below the surface of the water. Water tem-
perature was 30°C. The pool was located in a large test
room, where there were many clues external to the maze
(e.g., pictures, lamps); these were visible from the pool and
presumably used by the rats for spatial orientation. The po-
sition of the cues remained unchanged throughout the task.
Data collection was automated by the HVS Image 2020
Plus Tracking System (US HVS Image, San Diego, CA).
For descriptive data collection, the pool was subdivided
into four equal quadrants formed by imaging lines.
For the training trials, each animal received one trial per
day for a 5-day session, with a 2-day break between the
final training session and brain injury. The rats then were
tested on days 1, 4, 8, and 15 after TBI or surgery. At the
start of a trial, the rat was placed randomly at one of four
fixed starting points, randomly facing either toward the
wall or inwardly (designated North, South, East, and West)
and allowed to swim for 90 sec or until they found the
platform. The platform was located in a randomly chang-
ing position within the NE quadrant throughout the test pe-
riod (e.g., sometimes, equidistant from the center and edge
of the pool, against the wall, near the center of the pool,
and at the edges of the NE quadrant). The goal was to
make the daily mean of trials comparable to that of a stan-
dard probe trial without removing the platform and with-
out being confounded by a single starting place (as in the
standard probe trial). The animal learns to search exten-
sively in the correct quadrant, because the platform is lo-
cated somewhere within the NE quadrant but its precise
location cannot be predicted.
In the standard fixed placement of the platform, the
animals, once they learn the location, do not need to
spend much search time in the quadrant, and when the
platform is removed for the occasional brief probe trial,
the animal quickly discovers its absence and may spend
only a small amount of time searching for it again in that
location. Moreover, the maladaptive preservative perfor-
mance can increase the percentage of time an animal
spends in the vicinity of the location from which a fixed-
location platform is removed during a probe trial.
In each training session, the latency to escape onto the
hidden platform was recorded. If the animal found the
platform, it was allowed to remain there for 15 sec be-
fore being returned to its home cage. If the animal was
unable to find the platform within 90 sec, the training
was terminated and a maximum score of 90 sec was as-
signed. The percentage of time traveled within the NE
(correct) quadrant was calculated relative to the total
amount of time spent swimming before reaching the plat-
form.
Statistical Analysis
Data were analyzed by ANOVA followed by t-test for
multiple comparisons. Paired t-test was used to test the
difference of cell counts between the ipsilateral and the
contralateral hemispheres or between different groups.
All measurements were performed by observers blinded
to individual treatment.
RESULTS
Erythropoietin Enhances the Restoration of
Spatial Memory
All rats were trained for 5 days before surgery. At the
first day of training, the percentage of the mean time spent
in the correct quadrant (containing the platform) was ap-
proximately 25% (chance level), which then persistently
increased during the subsequent training days, reaching
about 50% after the five daily training sessions (Fig. 1).
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FIG. 1. Plot shows the temporal profile of the time spent in
the correct quadrant (mean   SD%). Percentage of time spent
in the correct quadrant by the rats receiving 5 days of training
reached  50% and then significantly declined to  25%, re-
sembling the first-day training level at 1 day after traumatic
brain injury (TBI). At 15 days after TBI treatment (14-day treat-
ment), the percentage of time spent by the erythropoietin
(EPO)–treated rats in the correct quadrant was significantly el-
evated versus the saline-treated TBI rats (*p   0.05). These
data demonstrate that TBI in the controlled cortical impact
model in rat significantly reduces the spatial memory and EPO
treatment promotes restoration of spatial memory.The average time spent in each of the other quadrants de-
creased over the 5-day training trial to about 17% (be-
low chance). At day 7 after the start of the experiment,
all rats were subjected to TBI, and at day 1 after TBI, the
rats showed a significantly diminished percentage of time
spent in the correct quadrant, close to the chance levels
of the time spent at the start of the training (Fig. 1). These
data demonstrate that damage to brain in this model with
the current degree of injury causes significant dysfunc-
tion of spatial memory in rats, which can be used as a
target for the treatment of the injury. The degree of pre-
training was purposely limited so that overtraining did
not occur.
Rats were tested at day 1 after TBI just prior to treat-
ment, and at days 4, 8, and 15 after TBI (3, 7, and 14
days after initiation of treatment). The percentage of time
spent in the correct quadrant was significantly higher in
the EPO-treated group versus the saline-treated group at
day 15 (43.0   6.6% vs. 31.0   3.5%) after TBI (p  
0.05) (Fig. 1). These data demonstrate that EPO admin-
istration reduces the dysfunction of the spatial memory
caused by the brain damage in this model.
EPO Increases the Number of BrdU-Labeled
Cells in the DG
In this study, our focus is on spatial memory recovery
after TBI, consequently BrdU-positive cells as an index
of neurogenesis were counted in the DG of the hip-
pocampus but not in other areas of brain. BrdU-labeled
cells were observed mainly in the subgranular zone and
the granular cell layer, and a few were found in the mo-
lecular layer of both the EPO-treated and the saline-
treated groups (Fig. 2a,b). Some BrdU-labeled cells ex-
pressed NeuN, a marker for mature neurons in the
granular cell layer (Fig. 2a,b). However, few BrdU-la-
beled cells were detected in the hilus of the DG in the
EPO-treated group (Fig. 2b). EPO administration for 14
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FIG. 2. Photographs show the floating double fluorescent staining for BrdU (green) and NeuN (red) to identify the newly gen-
erated cells and neurogenesis in the dentate gyrus (DG) of the ipsilateral hemisphere of the saline-treated (a) and the erythropoietin
(EPO)–treated (b) groups. Arrows indicate the BrdU-labeled cells colabeled with NeuN (yellow). Bar   50  m.
FIG. 3. Bar graphs show the density of BrdU-labeled cells (a) and the percentage of BrdU-labeled cells colabeled with NeuN
(b) in the dentate gyrus (DG) after traumatic brain injury (TBI) in rat. n   6 rats/group. *p   0.05, compared to the saline-treated
group.days significantly increased the number of BrdU-labeled
cells in both the contralateral and ipsilateral DG (51  
10 cells/mm2 and 142   17 cells/mm2, respectively)
compared to the saline-treated group (17   7 cells/mm2
and 36   12 cells/mm2; p   0.05) (Fig. 3a). Counting the
percentage of BrdU-labeled cells colabeled with NeuN,
EPO administration significantly increased the percent-
age of newly generated cells that differentiated into ma-
ture neurons in the granular cell layers of both the con-
tralateral and ipsilateral DG (Fig. 3b). These data
demonstrate that EPO administration increases neuroge-
nesis in the DG in rats after TBI.
DISCUSSION
The present study shows, for the first time, that treat-
ment of TBI with EPO promotes restoration of spatial
memory and enhances neurogenesis in the DG in rat.
Via a 5-day training regimen, rats learned and re-
membered spatial cues. Thereafter, they spent more time
finding the platform in the correct quadrant since the lo-
cation of the platform was changed. TBI destroyed this
spatial memory, leading the rats to swim purposelessly
in the pool after brain injury. Treatment with EPO pro-
motes restoration at 15 days after TBI compared to the
saline treatment, thereby demonstrating the benefits of
EPO treatment on memory restoration in TBI. EPO-in-
duced neurogenesis of the DG may contribute to spatial
memory restoration in this model of TBI, although the
therapeutic mechanisms are unclear. EPO gene expres-
sion can be induced and regulated by hypoxia, ischemia
and brain trauma (Tong and Nissenson 2001; Cerami et
al., 2002; Leist et al., 2004; Wen et al., 2004; Martinez-
Estrada et al., 2003; Aydin et al., 2003; Yu et al., 2002).
However, when comparing pre- and post-TBI functional
data, endogenous expression of the EPO gene is appar-
ently not sufficient to restore damaged brain tissue and
corresponding functional deficits. Exogenous adminis-
tration of EPO has been tested in many model systems
(e.g., treatment of stroke with EPO stimulates neurogen-
esis and angiogenesis in the injured brain and improves
functional recovery) (Wang et al., 2004a).
Inhibition or reduction of neurogenesis in the DG of
the rodent has been shown to reduce spatial memory
(Rhodes et al., 2003; van Praag et al., 1999). The nega-
tive impact of blocking neurogenesis has also been found
in rodents subjected to radiation escaping from a closed
container (Rola et al., 2004; Raber et al., 2004). Our pre-
vious studies on the amplification of neurogenesis by
means of cell-based or pharmacologically based thera-
pies after stroke and TBI (Lu et al., 2003; Mahmood et
al., 2004) demonstrate a significant improvement in func-
tional outcome and are consistent with concomitant EPO-
mediated neurogenesis and functional improvement after
TBI.
An additional finding in this study is that EPO pro-
motes differentiation of the newly generated cells into
neuronal phenotype in the DG. Differentiation of the
newly generated cells in the DG is dependent on the tis-
sue microenvironment (i.e., the presence of angiogenesis
and production of growth factors, such as brain-derived
neurotrophic factor (BDNF) (Kempermann et al., 2004).
Therefore, BDNF and vascular endothelial growth factor
(VEGF) induced by EPO, as previously shown (Wang et
al., 2004b), may also play an important role in the sur-
vival and differentiation of neural progenitor cells in the
DG after TBI. However, in-depth studies are needed to
demonstrate whether the newly generated neurons func-
tion as mature neurons.
EPO has an anti-apoptotic and neuroprotective effect
in many organs including brain (Buemi et al., 2003; Yu
et al., 2002). Thus, preventing the death of newly gener-
ated cells as a way to increase the number of newly gen-
erated neurons cannot be ruled out. Many studies have
shown that a large portion of the newly generated cells
in the subventricular zone and the DG die by undergo-
ing apoptosis (Kempermann et al., 2003). However, in
this study, we focus solely on the number of newly gen-
erated cells as the end point after EPO treatment. Addi-
tional studies are needed to evaluate the dynamic changes
of apoptosis at early time points, and the relative role of
neuroprotection and brain plasticity (e.g., neurogenesis
on improvement of spatial memory after TBI) in im-
proving functional recovery after TBI.
CONCLUSION
Our data demonstrate that EPO treatment promotes
spatial memory restoration and enhances the presence of
the newly formed neurons in the DG after TBI in the rat.
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